Advertisement
BRKR or TMO or WAT
Which Stock Would AI Choose? Bruker Corporation (BRKR) vs. Thermo Fisher Scientific Inc. (TMO) vs. Waters Corporation (WAT) Stock Comparison
Key Takeaways
- BRKR, TMO, and WAT operate in the life sciences and analytical instruments sector, with overlapping exposure to research, diagnostics, and pharmaceutical markets.
- Recent market activity shows varying price behavior influenced by earnings expectations and broader sector sentiment, with WAT approaching its Q2 2026 earnings release.
- TMO maintains the largest scale with annual revenue exceeding $45 billion, providing relative stability compared to the more specialized operations of BRKR and WAT.
- Valuation sensitivity and growth drivers differ, with each company positioned around instrument sales, consumables, and services amid ongoing life sciences demand.
- Sector exposure links all three to research funding trends and biopharma spending, creating correlated yet distinct risk profiles.
- Market positioning reflects trade-offs between scale (TMO), specialized instrumentation (BRKR and WAT), and upcoming catalysts such as earnings reports.
Introduction
BRKR, TMO, and WAT represent leading players in the scientific instruments and life sciences tools industry. Investors and traders focused on the healthcare and research sectors often examine these stocks together due to shared exposure to laboratory equipment, analytical technologies, and consumables demand. This comparison highlights relative performance, business models, and recent market dynamics to assist those evaluating portfolio allocation or sector rotation strategies within the life sciences space.
BRKR Overview and Recent Performance
Bruker Corporation develops and manufactures scientific instruments and analytical solutions primarily for life sciences, materials research, and industrial applications. In recent weeks, BRKR has experienced price movements aligned with broader life sciences sector trends and investor positioning ahead of potential catalysts. Sentiment has been shaped by ongoing demand for advanced instrumentation in research settings, though specific earnings updates or macroeconomic factors have contributed to measured trading activity without pronounced directional shifts.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. provides a comprehensive portfolio of analytical instruments, laboratory equipment, reagents, and services to support research, diagnostics, and pharmaceutical development. With its substantial scale, TMO has shown relative resilience in recent market activity, reflecting steady customer demand across its diversified offerings. Performance in recent weeks has been influenced by sector-wide sentiment and the company’s established market leadership, resulting in more stable price behavior compared to smaller peers.
WAT Overview and Recent Performance
Waters Corporation specializes in analytical instruments, particularly chromatography systems and mass spectrometry solutions used in pharmaceuticals, environmental testing, and food safety. Recent trading has featured fluctuations around the $376–$383 range as of late July 2026, with investors positioning ahead of the company’s Q2 2026 earnings call scheduled for August 4. Performance reflects typical pre-earnings volatility and broader interest in life sciences instrumentation demand.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots from hundreds available on the platform. These bots trade thousands of different tickers using varied strategies, timeframes, and performance metrics. Only those demonstrating strong suitability for prevailing market conditions earn placement in the trending section, which highlights options with diverse risk profiles, historical returns, and ticker coverage. Readers can explore the full range of bots to identify approaches matching their trading preferences.
Head-to-Head Comparison
BRKR, TMO, and WAT share core exposure to the life sciences tools sector yet differ in scale and focus. TMO’s broad revenue base exceeding $45 billion supports greater diversification across instruments, consumables, and services compared to the more targeted instrumentation portfolios of BRKR and WAT. Recent momentum has varied, with WAT exhibiting pre-earnings movement while TMO has maintained steadier positioning. Risk factors include sensitivity to research funding cycles and biopharma capital spending for all three, though TMO’s size may moderate volatility. Valuation considerations often center on growth in high-margin recurring revenue streams, with market sentiment reflecting sector rotation and macroeconomic influences on laboratory investments.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings visibility, and relative sector positioning, Tickeron’s AI would currently assign a probabilistic preference toward TMO for its scale-driven stability and diversified revenue streams, while noting WAT’s upcoming earnings as a potential near-term catalyst and BRKR’s specialized exposure as offering differentiated opportunities depending on research spending trends.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BRKR’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 3 green FA rating(s), and WAT’s FA Score reflects 2 green FA rating(s).
- BRKR’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 3 green, 2 red.
- WAT’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BRKR’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 3 bullish TA indicator(s), and WAT’s TA Score reflects 5 bullish TA indicator(s).
- BRKR’s TA Score: 3 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 4 bearish.
- WAT’s TA Score: 5 bullish, 4 bearish.
Price Growth
BRKR (@Medical/Nursing Services) experienced а -15.01% price change this week, while TMO (@Medical Specialties) price change was +3.43% , and WAT (@Medical Specialties) price fluctuated +7.83% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +5.89%. For the same industry, the average monthly price growth was -1.59%, and the average quarterly price growth was -8.72%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.88%. For the same industry, the average monthly price growth was +8.02%, and the average quarterly price growth was +20.04%.
Reported Earning Dates
BRKR is expected to report earnings on Oct 29, 2026.
TMO is expected to report earnings on Oct 28, 2026.
WAT is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Medical/Nursing Services (+5.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+6.88% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BRKR | TMO | WAT | |
| Capitalization | 8.14B | 220B | 39.9B |
| EBITDA | 306M | 12B | 991M |
| Gain YTD | 13.642 | 2.715 | 7.116 |
| P/E Ratio | 74.88 | 31.97 | 103.00 |
| Revenue | 3.46B | 46.3B | 3.77B |
| Total Cash | N/A | 4.06B | 462M |
| Total Debt | 1.67B | 42.5B | 5.57B |
BRKR | TMO | WAT | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 39 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 12 Undervalued | 75 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | 87 | |
SMR RATING 1..100 | 92 | 61 | 85 | |
PRICE GROWTH RATING 1..100 | 42 | 12 | 20 | |
P/E GROWTH RATING 1..100 | 6 | 31 | 4 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (12) in the Medical Specialties industry is in the same range as BRKR (32) and is somewhat better than the same rating for WAT (75). This means that TMO's stock grew similarly to BRKR’s and somewhat faster than WAT’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as WAT (87) and is in the same range as BRKR (100). This means that TMO's stock grew similarly to WAT’s and similarly to BRKR’s over the last 12 months.
TMO's SMR Rating (61) in the Medical Specialties industry is in the same range as WAT (85) and is in the same range as BRKR (92). This means that TMO's stock grew similarly to WAT’s and similarly to BRKR’s over the last 12 months.
TMO's Price Growth Rating (12) in the Medical Specialties industry is in the same range as WAT (20) and is in the same range as BRKR (42). This means that TMO's stock grew similarly to WAT’s and similarly to BRKR’s over the last 12 months.
WAT's P/E Growth Rating (4) in the Medical Specialties industry is in the same range as BRKR (6) and is in the same range as TMO (31). This means that WAT's stock grew similarly to BRKR’s and similarly to TMO’s over the last 12 months.
| BRKR | TMO | WAT | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 62% | 3 days ago 69% |
| Stochastic ODDS (%) | 3 days ago 72% | 3 days ago 61% | 3 days ago 72% |
| Momentum ODDS (%) | 3 days ago 70% | N/A | 3 days ago 63% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 63% | 3 days ago 57% |
| TrendWeek ODDS (%) | 3 days ago 73% | 3 days ago 61% | 3 days ago 63% |
| TrendMonth ODDS (%) | 3 days ago 77% | 3 days ago 61% | 3 days ago 60% |
| Advances ODDS (%) | N/A | 3 days ago 61% | 5 days ago 62% |
| Declines ODDS (%) | 14 days ago 73% | 6 days ago 63% | 7 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 84% | 3 days ago 56% | 3 days ago 87% |
| Aroon ODDS (%) | 3 days ago 62% | 3 days ago 57% | N/A |
Advertisement
WAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, WAT has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if WAT jumps, then A could also see price increases.
| Ticker / NAME | Correlation To WAT | 1D Price Change % | ||
|---|---|---|---|---|
| WAT | 100% | +1.79% | ||
| A - WAT | 68% Closely correlated | +3.28% | ||
| RVTY - WAT | 64% Loosely correlated | +0.37% | ||
| TMO - WAT | 60% Loosely correlated | +2.41% | ||
| BRKR - WAT | 58% Loosely correlated | +4.17% | ||
| CRL - WAT | 56% Loosely correlated | +0.75% | ||
More | ||||